Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Valentin Fuster,
Dr. Borge Nordestgaard
Presenter | see Discussant report
Borge Nordestgaard, (Denmark)
List of Authors: Anne Langsted, MD, Jacob J Freiberg, MD, Anne Tybjærg-Hansen, MD, DMSc, Peter Schnohr, MD, DMSc, Gorm B Jensen, MD, DMSc, and Børge G Nordestgaard MD, DMSc.
Context: Current guidelines recommend identification and treatment of elevated cholesterol levels, but not of nonfasting triglycerides. Objective: We compared the ability of cholesterol and triglycerides measured nonfasting at random to predict risk of myocardial infarction and total mortality. Design, setting, and participants: We followed 7581 women and 6391 men aged 20 to 93 years from the Danish general population for 31 years. Among women, 768 developed myocardial infarction and 4398 died; corresponding numbers in men were 1151 and 4416. Follow-up was 100% complete. Main outcome measures: Plasma cholesterol and triglycerides measured nonfasting at random, lipoproteins, traditional cardiovascular risk factors and endpoints. Results: Elevated nonfasting total cholesterol mainly marked elevated low density lipoprotein cholesterol levels while elevated nonfasting triglyceride levels mainly marked elevated remnant lipoprotein cholesterol levels. Compared to women with cholesterol <5mmol/L, multivariate adjusted hazard ratios for myocardial infarction ranged from 1.3(95%CI 0.9-1.8) for cholesterol of 5-5.99 mmol/L to 2.5 (1.6-4.0) for cholesterol =9mmol/L (trend p<0.0001), while compared with women with nonfasting triglycerides <1 mmol/L, hazard ratios ranged from 1.5 (1.2-1.8) for triglycerides of 1-1.99 mmol/L to 4.2(2.5-7.2) for triglycerides =5mmol/L (p<0.0001). In men, corresponding hazard ratios ranged from 1.2 (1.0-1.5) to 5.3 (3.6-8.0) for cholesterol (p<0.0001), and from 1.3(1.0-1.6) to 2.1 (1.5-2.8) for triglycerides (p<0.0001). Increasing cholesterol levels did not consistently associate with total mortality in women (trend p=0.39) or men (p=0.02). In contrast, compared with women with triglycerides <1 mmol/L, multivariate adjusted hazard ratios for total mortality ranged from 1.1 (1.0-1.2) for triglycerides of 1-1.99 mmol/L to 2.0(1.5-2.9) for triglycerides =5mmol/L (trend p<0.0001); corresponding hazard ratios in men ranged from 1.1(1.0-1.2) to 1.5(1.2-1.7) (p<0.0001). Conclusion: Stepwise increasing levels of both nonfasting cholesterol and nonfasting triglycerides associate with stepwise increasing risk of myocardial infarction; however, only increasing levels of nonfasting triglycerides consistently associate with total mortality.
Discussant | see Presenter abstract
Valentin Fuster, FESC (United States of America)
Nonfasting cholesterol and triglycerides, myocardial infarction, and early death. Copenhagen City Heart
This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.
© 2016 European Society of Cardiology. All rights reserved